Freeline Therapeutics

Freeline Therapeutics

Verified
Biopharmaceutical focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders

Launch date
Employees
Ownership
Market cap
$50m
Net debt
$32.6m
Firm valuation
$17m (Public information from Sep 2022)
Stevenage England (HQ)

Financials

Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022E
Revenues--<1m----
EBITDA-(20m)(40m)(60m)---
% EBITDA margin--(10000 %)----
Profit-10m20m300m---
% profit margin--5000 %----

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
N/ASpinout
$38mSeries A
£1mSeries A
$116mSeries B
N/AN/AGrant
Not yet verified
$40mSeries C
$80mSeries C
N/A$159m
Valuation: $467m
IPO
Total Funding$275m

Recent News about Freeline Therapeutics

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.